• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Letter re: The efficacy of immunotherapy combined with capecitabine versus immunotherapy alone as maintenance therapy in patients with de novo metastatic nasopharyngeal carcinoma: a retrospective propensity score matching study.

作者信息

Sahin T K, Guven D C

机构信息

Department of Medical Oncology, Hacettepe University, Ankara, Turkey.

Department of Medical Oncology, Hacettepe University, Ankara, Turkey.

出版信息

ESMO Open. 2025 Aug 12;10(8):105566. doi: 10.1016/j.esmoop.2025.105566.

DOI:10.1016/j.esmoop.2025.105566
PMID:40803017
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12361762/
Abstract
摘要

相似文献

1
Letter re: The efficacy of immunotherapy combined with capecitabine versus immunotherapy alone as maintenance therapy in patients with de novo metastatic nasopharyngeal carcinoma: a retrospective propensity score matching study.信件回复：免疫疗法联合卡培他滨与单纯免疫疗法作为初治转移性鼻咽癌患者维持治疗的疗效：一项回顾性倾向评分匹配研究
ESMO Open. 2025 Aug 12;10(8):105566. doi: 10.1016/j.esmoop.2025.105566.
2
The efficacy of immunotherapy combined with capecitabine versus immunotherapy alone as maintenance therapy in patients with de novo metastatic nasopharyngeal carcinoma: a retrospective propensity score matching study.免疫疗法联合卡培他滨与单纯免疫疗法作为初治转移性鼻咽癌患者维持治疗的疗效：一项回顾性倾向评分匹配研究
ESMO Open. 2025 Jun;10(6):105295. doi: 10.1016/j.esmoop.2025.105295. Epub 2025 Jun 3.
3
Anti-PD-1 antibody with or without capecitabine as maintenance therapy after first-line therapy of recurrent or metastatic nasopharyngeal carcinoma.抗程序性死亡蛋白1（PD-1）抗体联合或不联合卡培他滨作为复发性或转移性鼻咽癌一线治疗后的维持治疗。
Oncologist. 2025 Jul 4;30(7). doi: 10.1093/oncolo/oyaf188.
4
Immunotherapy combined with chemotherapy without locoregional radiotherapy in metastatic nasopharyngeal carcinoma: two case reports and a literature review.免疫疗法联合化疗用于转移性鼻咽癌且未行局部区域放疗：两例病例报告及文献综述
Front Immunol. 2025 Jan 9;15:1467355. doi: 10.3389/fimmu.2024.1467355. eCollection 2024.
5
The role of capecitabine as maintenance therapy in de novo metastatic nasopharyngeal carcinoma: A propensity score matching study.卡培他滨作为新诊断转移性鼻咽癌维持治疗的作用：一项倾向评分匹配研究。
Cancer Commun (Lond). 2020 Jan;40(1):32-42. doi: 10.1002/cac2.12004. Epub 2020 Feb 29.
6
Efficacy of local-regional radiotherapy in de novo metastatic nasopharyngeal carcinoma patients receiving chemo-immunotherapy: A multicenter, propensity score matching study.局部区域放疗在接受化疗免疫治疗的初诊转移性鼻咽癌患者中的疗效：一项多中心倾向评分匹配研究
Radiother Oncol. 2025 Feb;203:110687. doi: 10.1016/j.radonc.2024.110687. Epub 2024 Dec 19.
7
Efficacy and optimal duration of maintenance immunotherapy following systemic chemoimmunotherapy and locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A multicenter retrospective cohort study.初治转移性鼻咽癌全身化疗联合免疫治疗及局部区域放疗后维持免疫治疗的疗效和最佳持续时间：一项多中心回顾性队列研究
Int J Cancer. 2025 Jul 1;157(1):139-150. doi: 10.1002/ijc.35382. Epub 2025 Feb 24.
8
Impact of first-line chemoimmunotherapy with or without radiotherapy on the prognosis of patients with locally advanced or metastatic esophageal squamous cell carcinoma: a multicenter, real-world, retrospective cohort study from China (NCT06478355).一线化疗免疫治疗联合或不联合放疗对局部晚期或转移性食管鳞状细胞癌患者预后的影响：一项来自中国的多中心、真实世界、回顾性队列研究（NCT06478355）
Front Immunol. 2025 Jul 28;16:1633930. doi: 10.3389/fimmu.2025.1633930. eCollection 2025.
9
Real-world comparison of chemotherapy plus bevacizumab with or without immunotherapy as first-line therapy in colorectal cancer.化疗联合贝伐单抗加或不加免疫疗法作为结直肠癌一线治疗的真实世界比较
World J Gastroenterol. 2025 Jun 28;31(24):108298. doi: 10.3748/wjg.v31.i24.108298.
10
Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial.卡培他滨维持治疗残留鼻咽癌患者：一项单臂II期试验
Clin Cancer Res. 2025 Aug 1;31(15):3133-3141. doi: 10.1158/1078-0432.CCR-24-4132.

本文引用的文献

1
The efficacy of immunotherapy combined with capecitabine versus immunotherapy alone as maintenance therapy in patients with de novo metastatic nasopharyngeal carcinoma: a retrospective propensity score matching study.免疫疗法联合卡培他滨与单纯免疫疗法作为初治转移性鼻咽癌患者维持治疗的疗效：一项回顾性倾向评分匹配研究
ESMO Open. 2025 Jun;10(6):105295. doi: 10.1016/j.esmoop.2025.105295. Epub 2025 Jun 3.
2
Updates on Treatments and Management of Nasopharyngeal Carcinoma.
Am Soc Clin Oncol Educ Book. 2025 Jun;45(3):e472460. doi: 10.1200/EDBK-25-472460. Epub 2025 Apr 10.
3
Immunotherapy in the First-Line Treatment of Advanced Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis.免疫疗法在晚期鼻咽癌一线治疗中的应用：系统评价和荟萃分析。
Laryngoscope. 2024 Jan;134(1):7-17. doi: 10.1002/lary.30754. Epub 2023 May 25.
4
Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III Trial.吉西他滨和顺铂诱导化疗治疗鼻咽癌的最终总生存分析：一项多中心、随机 III 期试验。
J Clin Oncol. 2022 Aug 1;40(22):2420-2425. doi: 10.1200/JCO.22.00327. Epub 2022 Jun 16.
5
Effect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma Who Had Received Induction Chemotherapy: A Phase 3 Randomized Clinical Trial.卡培他滨维持治疗联合最佳支持治疗对比单纯最佳支持治疗对接受诱导化疗的初诊转移性鼻咽癌患者无进展生存期的影响：一项 3 期随机临床试验。
JAMA Oncol. 2022 Apr 1;8(4):553-561. doi: 10.1001/jamaoncol.2021.7366.